Human CTLs to Wild-Type and Enhanced Epitopes of a Novel Prostate and Breast Tumor-Associated Protein, TARP, Lyse Human Breast Cancer Cells

Sang Kon Oh, Masaki Terabe, C. David Pendleton, Anu Bhattacharyya, Tapan K. Bera, Malka Epel, Yoram Reiter, John Phillips, W. Marston Linehan, Claude Sportes, Ira Pastan, Jay A. Berzofsky

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

Vaccine therapy for prostate and breast cancer may have potential for treating these major causes of death in males and females, respectively. Critical to the development of tumor-specific vaccines is finding and characterizing novel antigens to be recognized by CD8+ T cells. To define new CD8+ T-cell tumor antigens, we determined two wild-type HLA-A2 epitopes from a recently found tumor-associated protein, TARP (T-cell receptor γ alternate reading frame protein), expressed in prostate and breast cancer cells. We were also able to engineer epitope-enhanced peptides by sequence modifications. Both wild-type and enhanced epitopes induced peptide-specific CD8+ T-cell responses in A2Kb transgenic mice. In vitro restimulation of human CD8+ T cells from a prostate cancer patient resulted in CD8+ T cells reactive to the peptide epitopes that could lyse HLA-A2+ human breast cancer cells (MCF-7) expressing TARP. Epitope-specific human CD8+ T cells were also enumerated in patients' peripheral blood by tetramer staining. Our data suggest that HLA-A2-binding TARP epitopes and enhanced epitopes discovered in this study could be incorporated into a potential vaccine for both breast and prostate cancer.

Original languageEnglish (US)
Pages (from-to)2610-2618
Number of pages9
JournalCancer Research
Volume64
Issue number7
DOIs
StatePublished - Apr 1 2004

Fingerprint

Prostate
Epitopes
Breast Neoplasms
T-Lymphocytes
HLA-A2 Antigen
Prostatic Neoplasms
Proteins
Peptides
Active Immunotherapy
Reading Frames
Cancer Vaccines
MCF-7 Cells
Neoplasm Antigens
T-Cell Antigen Receptor
TARP
Transgenic Mice
Cause of Death
Vaccines
Staining and Labeling
Antigens

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Oh, S. K., Terabe, M., Pendleton, C. D., Bhattacharyya, A., Bera, T. K., Epel, M., ... Berzofsky, J. A. (2004). Human CTLs to Wild-Type and Enhanced Epitopes of a Novel Prostate and Breast Tumor-Associated Protein, TARP, Lyse Human Breast Cancer Cells. Cancer Research, 64(7), 2610-2618. https://doi.org/10.1158/0008-5472.CAN-03-2183

Human CTLs to Wild-Type and Enhanced Epitopes of a Novel Prostate and Breast Tumor-Associated Protein, TARP, Lyse Human Breast Cancer Cells. / Oh, Sang Kon; Terabe, Masaki; Pendleton, C. David; Bhattacharyya, Anu; Bera, Tapan K.; Epel, Malka; Reiter, Yoram; Phillips, John; Linehan, W. Marston; Sportes, Claude; Pastan, Ira; Berzofsky, Jay A.

In: Cancer Research, Vol. 64, No. 7, 01.04.2004, p. 2610-2618.

Research output: Contribution to journalArticle

Oh, SK, Terabe, M, Pendleton, CD, Bhattacharyya, A, Bera, TK, Epel, M, Reiter, Y, Phillips, J, Linehan, WM, Sportes, C, Pastan, I & Berzofsky, JA 2004, 'Human CTLs to Wild-Type and Enhanced Epitopes of a Novel Prostate and Breast Tumor-Associated Protein, TARP, Lyse Human Breast Cancer Cells', Cancer Research, vol. 64, no. 7, pp. 2610-2618. https://doi.org/10.1158/0008-5472.CAN-03-2183
Oh, Sang Kon ; Terabe, Masaki ; Pendleton, C. David ; Bhattacharyya, Anu ; Bera, Tapan K. ; Epel, Malka ; Reiter, Yoram ; Phillips, John ; Linehan, W. Marston ; Sportes, Claude ; Pastan, Ira ; Berzofsky, Jay A. / Human CTLs to Wild-Type and Enhanced Epitopes of a Novel Prostate and Breast Tumor-Associated Protein, TARP, Lyse Human Breast Cancer Cells. In: Cancer Research. 2004 ; Vol. 64, No. 7. pp. 2610-2618.
@article{6ce314f6330a4a568989df6aee1621a4,
title = "Human CTLs to Wild-Type and Enhanced Epitopes of a Novel Prostate and Breast Tumor-Associated Protein, TARP, Lyse Human Breast Cancer Cells",
abstract = "Vaccine therapy for prostate and breast cancer may have potential for treating these major causes of death in males and females, respectively. Critical to the development of tumor-specific vaccines is finding and characterizing novel antigens to be recognized by CD8+ T cells. To define new CD8+ T-cell tumor antigens, we determined two wild-type HLA-A2 epitopes from a recently found tumor-associated protein, TARP (T-cell receptor γ alternate reading frame protein), expressed in prostate and breast cancer cells. We were also able to engineer epitope-enhanced peptides by sequence modifications. Both wild-type and enhanced epitopes induced peptide-specific CD8+ T-cell responses in A2Kb transgenic mice. In vitro restimulation of human CD8+ T cells from a prostate cancer patient resulted in CD8+ T cells reactive to the peptide epitopes that could lyse HLA-A2+ human breast cancer cells (MCF-7) expressing TARP. Epitope-specific human CD8+ T cells were also enumerated in patients' peripheral blood by tetramer staining. Our data suggest that HLA-A2-binding TARP epitopes and enhanced epitopes discovered in this study could be incorporated into a potential vaccine for both breast and prostate cancer.",
author = "Oh, {Sang Kon} and Masaki Terabe and Pendleton, {C. David} and Anu Bhattacharyya and Bera, {Tapan K.} and Malka Epel and Yoram Reiter and John Phillips and Linehan, {W. Marston} and Claude Sportes and Ira Pastan and Berzofsky, {Jay A.}",
year = "2004",
month = "4",
day = "1",
doi = "10.1158/0008-5472.CAN-03-2183",
language = "English (US)",
volume = "64",
pages = "2610--2618",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "7",

}

TY - JOUR

T1 - Human CTLs to Wild-Type and Enhanced Epitopes of a Novel Prostate and Breast Tumor-Associated Protein, TARP, Lyse Human Breast Cancer Cells

AU - Oh, Sang Kon

AU - Terabe, Masaki

AU - Pendleton, C. David

AU - Bhattacharyya, Anu

AU - Bera, Tapan K.

AU - Epel, Malka

AU - Reiter, Yoram

AU - Phillips, John

AU - Linehan, W. Marston

AU - Sportes, Claude

AU - Pastan, Ira

AU - Berzofsky, Jay A.

PY - 2004/4/1

Y1 - 2004/4/1

N2 - Vaccine therapy for prostate and breast cancer may have potential for treating these major causes of death in males and females, respectively. Critical to the development of tumor-specific vaccines is finding and characterizing novel antigens to be recognized by CD8+ T cells. To define new CD8+ T-cell tumor antigens, we determined two wild-type HLA-A2 epitopes from a recently found tumor-associated protein, TARP (T-cell receptor γ alternate reading frame protein), expressed in prostate and breast cancer cells. We were also able to engineer epitope-enhanced peptides by sequence modifications. Both wild-type and enhanced epitopes induced peptide-specific CD8+ T-cell responses in A2Kb transgenic mice. In vitro restimulation of human CD8+ T cells from a prostate cancer patient resulted in CD8+ T cells reactive to the peptide epitopes that could lyse HLA-A2+ human breast cancer cells (MCF-7) expressing TARP. Epitope-specific human CD8+ T cells were also enumerated in patients' peripheral blood by tetramer staining. Our data suggest that HLA-A2-binding TARP epitopes and enhanced epitopes discovered in this study could be incorporated into a potential vaccine for both breast and prostate cancer.

AB - Vaccine therapy for prostate and breast cancer may have potential for treating these major causes of death in males and females, respectively. Critical to the development of tumor-specific vaccines is finding and characterizing novel antigens to be recognized by CD8+ T cells. To define new CD8+ T-cell tumor antigens, we determined two wild-type HLA-A2 epitopes from a recently found tumor-associated protein, TARP (T-cell receptor γ alternate reading frame protein), expressed in prostate and breast cancer cells. We were also able to engineer epitope-enhanced peptides by sequence modifications. Both wild-type and enhanced epitopes induced peptide-specific CD8+ T-cell responses in A2Kb transgenic mice. In vitro restimulation of human CD8+ T cells from a prostate cancer patient resulted in CD8+ T cells reactive to the peptide epitopes that could lyse HLA-A2+ human breast cancer cells (MCF-7) expressing TARP. Epitope-specific human CD8+ T cells were also enumerated in patients' peripheral blood by tetramer staining. Our data suggest that HLA-A2-binding TARP epitopes and enhanced epitopes discovered in this study could be incorporated into a potential vaccine for both breast and prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=11144357604&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=11144357604&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-03-2183

DO - 10.1158/0008-5472.CAN-03-2183

M3 - Article

C2 - 15059918

AN - SCOPUS:11144357604

VL - 64

SP - 2610

EP - 2618

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 7

ER -